<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01817283</url>
  </required_header>
  <id_info>
    <org_study_id>CACTRIP12</org_study_id>
    <nct_id>NCT01817283</nct_id>
  </id_info>
  <brief_title>Impact on T Cell Immune Activation and Inflammation of Triptolide Woldifii in HIV-infected Immunological Non-responders</brief_title>
  <acronym>CACTrip12</acronym>
  <official_title>Study of Triptolide Woldifiion T Cell Immune Activation and Inflammation Biomarkers in HIV-infected Immunological Non-responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LI Taisheng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, multicenter, randomized, placebo-controlled clinical trial, to
      evaluate impact of Triptolide wilfordii on T cell immune activation and inflammation
      biomarkers in HIV-infected immunological non-responders.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 120 patients will be recruited from 4 HIV/AIDS clinical centers in China and randomized
      1:1 into intervention group and placebo-controlled group. Triptolide wilfordii (20mg tid po)
      would be given to invention group for 24 weeks. T cell activation and inflammation biomarkers
      including CD8+HLA-DR+CD38+, IL-6, D-Dimer and high-sensitivity C-reactive protein (hsCRP),
      protein degradation-1 (PD-1), Ki67 ,soluble CD14 and CD163, PD-1, CCR5 and CD57 would be
      tested. Patients in placebo-controlled group will change to take Triptolide wilfordii (20mg
      tid po) for another 24 weeks. All patients will be followed up till 48 weeks. We hypothesis
      that Triptolide wilfordii might reduce immune activation and inflammation of HIV
      immunological non-responders and increase CD4 T cell count, which provides a new strategy for
      treatment of HIV-infected immunological non-responders.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of T cell immune activation and inflammation biomarkers</measure>
    <time_frame>baseline and at 4,8,12,24,36,48 weeks</time_frame>
    <description>T cell activation and inflammatory biomarkers including CD8+HLA-DR+/CD38+, IL-6, D-dimer and hsCRP,soluble CD14 and CD163, PD-1, CCR5 and CD57 should be measured at baseline and at Wee4, W12, W24, W36, W48 follow-up visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of CD4 T cell count and number of participants with adverse events</measure>
    <time_frame>baseline and at 4,8,12,24,36,48 weeks</time_frame>
    <description>Measurement of CD4 T cell count at baseline and different visit points when follow-up and numbers of participants with adverse events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>placebo + cART</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>combined with antiretroviral therapy, the control group will take placebo 2 tabs tid per day lasting for 6 months and then switch to take Triplitode 2 tabs tid po for anther 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triptolide + cART</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combined antiretroviral therapy, the experimental group will take Triptolide 2 tabs tid po per day for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triptolide</intervention_name>
    <description>Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.</description>
    <arm_group_label>placebo + cART</arm_group_label>
    <arm_group_label>Triptolide + cART</arm_group_label>
    <other_name>Tripterygium Wilfordii Hook F (TwHF)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cART</intervention_name>
    <description>Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.</description>
    <arm_group_label>placebo + cART</arm_group_label>
    <arm_group_label>Triptolide + cART</arm_group_label>
    <other_name>Antiretroviral therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo pills produced the same as Triptolide wilfordii.</description>
    <arm_group_label>placebo + cART</arm_group_label>
    <other_name>sugar pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Continuous antiretroviral therapy &gt; 24 months ， and consistent HIV-RNA&lt; 40 copies/mL
             more than 12 months ;

          -  18-65 years old;

          -  Male or female;

          -  Good adherence and promise to follow-up;

          -  Inform Consent signed;

          -  CD4 T cells less than 250/ul .

        Exclusion Criteria:

          -  Active opportunistic infection (not stable within 4 weeks 2 weeks ) or AIDS-related
             carcinoma;

          -  hemoglobin (HGB) &lt; 9 g/dl 、 white blood cell (WBC) &lt; 2000/ul 、 granulin (GRN) &lt; 1000
             /ul 、 platelet (PLT) &lt; 75000 /ul 、 Cr &gt;1.5x ULN 、 ALT or AST or alkaline phosphatase
             (ALP) &gt;3x upper limit of normal (ULN) 、 total bilirubin (TBIL) &gt;2x ULN 、 creatine
             kinase (CK) &gt; 2x ULN;

          -  Pregnant or breastfeeding woman or woman with pregnancy plan;

          -  Active drug-user;

          -  Severe neurological defects;

          -  Active alcohol abuse;

          -  Severe gastrointestinal ulcer .

          -  End-stage disease such as cirrhosis, chronic obstructive pulmonary disease, congestive
             heart failure, recent myocardial ischemia,tumor, etc

          -  Those who are undertaking steroids, immunomodulator, anti-inflammatory agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tai sheng LI, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei LU, M.D.</last_name>
    <phone>00861069155081</phone>
    <email>lvweipumch@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei LU, M.D.</last_name>
      <phone>00861069155081</phone>
      <email>lvweipumch@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2013</study_first_submitted>
  <study_first_submitted_qc>March 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2013</study_first_posted>
  <last_update_submitted>March 22, 2013</last_update_submitted>
  <last_update_submitted_qc>March 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College</investigator_affiliation>
    <investigator_full_name>LI Taisheng</investigator_full_name>
    <investigator_title>Peking Union Medical College Hospital</investigator_title>
  </responsible_party>
  <keyword>HIV-infected immunological non-responders</keyword>
  <keyword>Triptolide</keyword>
  <keyword>immune activation</keyword>
  <keyword>inflammation</keyword>
  <keyword>CD4 T cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

